SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The company is now trading on Nasdaq with the ticker symbol SIBN.
The company markets iFuse and iFuse-3D minimally invasive surgical implant systems for the treatment of sacroiliac joint dysfunction. Since launch in 2009, >34,000 procedures have been performed by >1,700 surgeons globally. For 2017, the company posted revenue of US $48.0MM, +14.0% from 2016, and reported a year-to-date estimated revenue range of $39.6MM to $39.8MM as compared to $34.2MM same period in 2017.
SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The company is now trading on Nasdaq with the ticker symbol SIBN.
The company markets iFuse and iFuse-3D minimally invasive surgical implant systems for the treatment of sacroiliac joint dysfunction. Since launch in...
SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The company is now trading on Nasdaq with the ticker symbol SIBN.
The company markets iFuse and iFuse-3D minimally invasive surgical implant systems for the treatment of sacroiliac joint dysfunction. Since launch in 2009, >34,000 procedures have been performed by >1,700 surgeons globally. For 2017, the company posted revenue of US $48.0MM, +14.0% from 2016, and reported a year-to-date estimated revenue range of $39.6MM to $39.8MM as compared to $34.2MM same period in 2017.
Copy to clipboard 
